ReviewGenes & diseases2026
Carnosine Dipeptidase(Cndp): An emerging therapeutic target for metabolic diseases and cancers.
Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Neurotensin Brake on Exploratory Drive under Persistent Threat.bioRxiv : the preprint server for biology · 2026Article
- CNDP1 and Diabetic Kidney Disease: From Genetic Susceptibility to Therapeutic Targeting.Genes · 2026Review
- High-altitude polycythemia: State-of-the-art review.Therapeutic advances in hematology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic diseases, associated with high morbidity and mortality rates, pose a challenge to global public health and a significant burden on society. Since the discovery of carnosinase-2(CNDP2)-mediated synthesis of lactate and phenylalanine, which subsequently forms N-Lactoyl-Phenylalanine (Lac-Phe) to inhibit food intake and obesity, the carnosine dipeptidases (CNDPs)have attracted increasing scientific interest. Although the role of CNDP in diabetic nephropathy has been extensively studied, its role in other metabolic diseases remains unclear. In this study, we have overviewed the enzymatic and other roles of CNDP proteins focusing on recent research demonstrating the regulatory roles of CNDP on various metabolic diseases. Increasing evidence indicates that carnosinase-1(CNDP1) and carnosinase-2 are crucial for the management of metabolic diseases under both physiological and pathological conditions. Moreover, interest in the pharmacological modulators of CNDP has been steadily increasing. Overall, we suggest that CNDP can be considered a promising therapeutic target for the effective treatment of metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.